Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN 5 DEXTROSE IN PLASTIC CONTAINER versus LINCOMYCIN HYDROCHLORIDE.
Head-to-head clinical analysis: CLINDAMYCIN PHOSPHATE IN 5 DEXTROSE IN PLASTIC CONTAINER versus LINCOMYCIN HYDROCHLORIDE.
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, a lincosamide antibiotic. It reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits bacteriostatic activity against susceptible organisms.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
1200-2700 mg/day IV divided every 6-12 hours; typical adult dose: 600-900 mg IV every 8 hours.
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in adults with normal hepatic and renal function. In patients with severe hepatic impairment, half-life may increase to 8-12 hours. Renal impairment generally does not significantly alter half-life. In neonates, half-life ranges from 8-20 hours depending on gestational age.
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Approximately 10% of the administered dose is excreted unchanged in urine via glomerular filtration; about 90% is metabolized hepatically to inactive metabolites, which are excreted in bile and feces. Biliary excretion accounts for approximately 80% of total elimination, with enterohepatic recirculation.
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic